- This event has passed.
Celiac Disease on the Horizon
April 30 @ 7:45 am - 3:25 pm
A scientific program designed for those interested in the development of non-dietary therapies for celiac disease including adult and pediatric physicians, dietitians and nutritionists, scientists, industry (pharmaceutical, diagnostic, biotechnology and food and agriculture), investor/venture capitalists and patients. For more information or to register, visit: https://www.eventleaf.com/e/celiacdisease2023
AGENDA
Saturday, April 29
7:45 AM – 7:50 AM Welcoming Remarks Peter HR Green, MD — USA
7:50 AM – 8:05 AM Celiac disease case-finding vs. mass screening: different or converging strategies. Carlo Catassi, MD, MPH — Italy
8:05 AM – 8:20 AM How do we diagnose the undiagnosed celiac disease patients in the USA? Joseph Murray, MD — USA
8:20 AM – 8:35 AM What can we learn from potential celiac disease? Riccardo Troncone, MD — Italy
8:35 AM – 8:50 AM Discussion Moderated by Carol Semrad, MD — USA
8:50 AM – 9:05 AM The power of high-throughput experimentation on serological and genetic testing in celiac disease. Xaio-Fei Kong, MD, PhD
9:05 AM – 9:20 AM Does celiac disease occur in African Americans? Amanda Cartee, MD — USA
9:20 AM – 9:35 AM Health-related outcomes in screening programs: Take the path unknown. Marisa Stahl, MD — USA
9:35 AM – 9:50 AM Role of IL-2 in assessing celiac disease. Robert Anderson, MD, PhD
9:50 AM – 10:05 AM 2023 ACG Guidelines on Diagnosis: Debates and compromises. Alberto Rubio-Tapia, MD — USA
10:05 AM – 10:20 AM 2023 ACG Guidelines: Mucosal healing and shared decision making. Benjamin Lebwohl, MD, MS — USA
10:20 AM – 10:35 AM Discussion Moderated by Carol Semrad, MD
10:35 AM – 10:50 AM Break
10:50 AM – 11:05 AM Could it be colitis? Suneeta Krishnareddy, MD — USA
11:05 AM – 11:20 AM Refractory celiac disease. Christophe Cellier, MD — France
11:20 AM – 11:35 AM Pathology and molecular abnormalities underlying refractory celiac disease type 2. Govind Bhagat, MD — USA
11:35 AM – 11:50 AM Non-responsive celiac disease in children. Maureen Leonard, MD — USA
11:50 AM – 12:05 PM Seronegative celiac disease: how common and how to diagnose it? Knut Lundin, MD, PhD– Norway
12:05 PM – 12:20 PM Discussion Moderated by Suneeta Krishnareddy, MD — USA
12:20 PM – 1:30 PM Lunch
1:30 PM – 1:45 PM Behavioral interventions in celiac disease. Randi L. Wolf, PhD, MPH — USA
1:45 PM – 2:00 PM Update on gluten immunogenic peptides. Alfonso Rodriquez Herrera, MD, PhD — Italy
2:00 PM – 2:15 PM Monitoring of celiac disease: developing a consensus. Luca Elli, MD, PhD
2:15 PM – 2:30 PM Discussion Moderated by Peter HR Green, MD — USA
2:30 PM – 2:45 PM Gluten in medications–should we be worried? Jonas Zeitz, MD — Switzerland Diana Studerus, MSc — Switzerland
2:45 PM – 3:00 PM People avoiding gluten without celiac disease! Claire Jansson Knodell, MD — USA
3:00 PM – 3:15 PM Use of organoids in celiac disease research. Arnold Han, MD — USA
3:15 PM – 3:30 PM Pathogenesis of metabolic defects in celiac disease. Bana Jabri, MD, PhD — USA
3:30 PM – 3:45 PM Funding Opportunities in Celiac Disease Research and Management. Marilyn Geller — USA
3:45 PM – 4:00 PM Discussion Moderated by Peter HR Green, MD — USA
4:00 PM – 4:15 PM Break
4:15 PM – 4:30 PM Endoscopy in clinical trials. Amelie Therrien, MD — USA
4:30 PM – 4:45 PM Recruitment in celiac disease trials. Dawn Wiese Adams, MD — USA
4:45 PM – 5:00 PM Pediatric considerations. Ritu Verma, MD — USA
5:00 PM – 5:15 PM Beyond the patient information sheet: creativity talking to patients. (and your IRB) about clinical trials Vanessa Weisbrod — USA
5:15 PM – 5:30 PM Patient and parental attitudes toward research. Jacqueline Jossen, MD — USA
5:30 PM – 5:45 PM Discussion Moderated by Jacqueline Jossen, MD — USA
Sunday, April 30
7:45 AM – 8:05 AM AI in gastroenterology: colonoscopy and beyond. Ali Soroush, MD — USA
8:05 AM – 8:25 AM AI in celiac disease: where should we start, and where should we go? Rajendra Udyavara, PhD — Australia
8:25 AM – 8:45 AM Video capsule image interpretation. Suzanne K. Lewis, MD — USA
8:45 AM – 9:05 AM What more can we get out of video capsule analysis? Edward Ciaccio, PhD — USA
9:05 AM – 9:25 AM Predicting outcome in celiac disease. Renata Auricchio, MD — Italy
9:25 AM – 9:45 AM AI use for pathology analysis for celiac disease. Oliver Faust, PhD — UK
9:45 AM – 10:00 AM Discussion Moderated by Suzanne K. Lewis, MD — USA
10:00 AM – 10:20 AM What does industry require? Daniel Leffler, MD, MS — USA Francisco Leon, MD, PhD — USA
10:20 AM – 10:40 AM FDA Draft Guidelines Suna Seo, MD — USA Irena Lavine, MD — USA Food & Drug Administration (FDA)
10:40 AM – 11:00 AM Latiglutenase update. Jack Syage, PhD — USA
11:00 AM – 11:20 AM Engineering bacteriophage for the targeted delivery and sustained expression of therapeutic modalities. Brian D. Green, PhD — USA
11:20 AM – 11:40 AM TAK-062 update Daniel Leffler, MD, MS — USA
11:40 AM – 12:00 PM KAN-101 update. Kristie Grebe, PhD — USA
12:00 PM – 12:15 PM Discussion Moderated by Peter HR Green, MD — USA
12:15 PM – 1:00 PM Lunch
1:00 PM – 1:20 PM TG2 inhibition: rationale, results, and future. Detlef Schuppan, MD, PhD — Germany
1:20 PM – 1:40 PM Development of anti-HLA-DQ2.5/gluten peptides antibody (DONQ52). Kosuke Yamashita — Japan
1:40 PM – 2:00 PM Blocking multiple cytokines. Valentina Discepolo, MD, PhD — Italy
2:00 PM – 2:10 PM Comments from Equillium, Inc. Maple Fung, MD — USA
2:10 PM – 2:30 PM Understanding microbial mechanisms to advance microbial therapeutics in celiac disease. Heather Galipeau, PhD — Canada
2:30 PM – 2:50 PM Mechanistic aspects of celiac disease interception approaches Francisco Leon, MD, PhD — USA
2:50 PM – 3:10 PM Discussion Moderated by Peter HR Green, MD — USA
3:10 PM – 3:25 PM Wrap-up Benjamin Lebwohl, MD, MS — USA
